Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellectar Biosciences filings document the regulatory record of a Delaware clinical biopharmaceutical company developing cancer therapies through its PDC platform. Current reports furnish quarterly and annual financial results, corporate updates, Regulation FD disclosures, and other events related to iopofosine I 131, CLR 125 and regulatory communications for its oncology programs.
Registration statements and material-event reports describe securities offerings, shelf registration activity, registered direct offerings, private placements, common stock, pre-funded warrants, milestone-based warrants and warrant exercise inducement transactions. The filing record also covers exhibit disclosures, Inline XBRL cover data, incorporation status, securities-law classifications and financing agreements that shape CLRB's public-company capital structure.
Cellectar Biosciences reported a Q1 2026 net loss of $5.65M, narrower than $6.60M a year earlier, as operating expenses fell to $5.79M. Cash and cash equivalents were $8.35M versus $13.20M at December 31, 2025, with operating activities using $4.85M of cash in the quarter.
The company remains a pre‑revenue, late‑stage oncology biotech with an accumulated deficit of about $275M and substantial reliance on external financing. Management disclosed substantial doubt about its ability to continue as a going concern beyond the second quarter of 2027 without additional actions, despite approximately $37M of liquidity as of the financial statement issuance date.
Clinically, Cellectar highlighted strong follow‑up data from its CLOVER WaM trial in relapsed or refractory Waldenstrom’s macroglobulinemia, including an overall response rate of 83.6% and major response rate of 61.8%, and it is preparing a Phase 3 confirmatory study supported by a financing that includes up to $105M in milestone‑based securities.
Cellectar Biosciences, Inc. Chief Operating Officer Jarrod Longcor reported open-market purchases of common stock and warrants. On 2026-05-07, he bought 8,680 shares of common stock at $2.88 per share. He also bought 26,040 warrants at $0.01 per warrant, each exercisable for one share of common stock at an exercise price of $2.88.
After these transactions, his direct holdings increased to 20,451 common shares and 36,149 warrants. A footnote explains the warrants are split into Tranche A, Tranche B, and Tranche C, with terms of one, two, and five years, respectively, from the date of stockholder approval.
Cellectar Biosciences, Inc. director and Chief Executive Officer James V Caruso reported buying common stock and warrants in an open-market transaction. He purchased 8,680 shares of common stock at $2.88 per share and 26,040 warrants at $0.01 per warrant, each relating to common stock at a $2.88 exercise price. Following these transactions, he directly holds 20,318 shares of common stock and 36,076 warrants. A footnote explains that the warrants are divided into tranches with terms of one, two, and five years from the date of stockholder approval.
Cellectar Biosciences, Inc. ownership disclosure: Stonepine entities and Jon M. Plexico report beneficial ownership of 863,277 shares of Common Stock, representing 9.9% of the class.
The filing states the holdings comprise 196,930 shares plus prefunded warrants to acquire 912,075 shares (the warrants are "subject to a 9.99% beneficial ownership limitation"). The percent is calculated using 7,975,069 shares outstanding as of May 4, 2026, which the filing ties to a registered offering and a private placement closed on May 4, 2026.
Cellectar Biosciences entered financing deals combining a registered direct offering of 1,618,053 common shares and a concurrent private placement of 2,116,887 shares, 9,471,086 pre-funded warrants and three milestone warrant tranches of 13,206,026 each at exercise prices largely around $2.65–$2.88.
The gross proceeds are expected to be about $35 million before fees, with an 8% cash fee and additional warrant compensation to the placement agent. After issuing these shares, Cellectar will have 7,975,069 common shares outstanding, excluding any shares from warrant exercises.
The company plans to use net proceeds mainly for working capital and to support initiation of a Phase 3 trial of iopofosine I 131 for Waldenström macroglobulinemia. In Phase 2b WM data, iopofosine showed an 83.6% overall response rate, 61.8% major response rate, 17.8‑month median duration of response and 13.5‑month median progression‑free survival with mostly low‑grade, manageable toxicities.
Cellectar Biosciences is offering 1,618,053 shares of Common Stock at $2.65 per share, generating aggregate gross proceeds of $4,287,840.45. Net proceeds to the company are estimated at approximately $3.9 million, which the company intends to use for working capital and to support plans to initiate a Phase 3 trial for iopofosine I 131.
The offering is concurrent with a private placement that includes up to 39,618,078 Common Warrant Shares, 2,116,887 Private Placement Shares and 9,471,086 Prefunded Warrants. The Common Warrants have an exercise price of $2.65 and become exercisable following the Stockholder Approval Date; Series A/B/C Warrants expire one, two and five years after that date, respectively. Shares outstanding after the offering are based on 4,240,129 shares as of April 30, 2026.
Cellectar Biosciences, Inc. filed an amended annual report to add required Part III information on directors, executive officers, ownership, related-party transactions and auditor fees to its previously filed Form 10-K for the year ended December 31, 2025.
As of April 29, 2026, the company had 4,240,129 common shares outstanding, plus limited amounts of Series D and Series E preferred stock. The filing details board committee composition, confirms most directors are independent, and outlines equity compensation plans with 212,167 options outstanding and 100,651 shares remaining for future grants.
The amendment also summarizes a $24.5 million September 2023 private placement of Series E-1 preferred stock and warrants with several 5%+ holders and notes that subsequent warrant exercises and inducement warrants generated approximately $19.4 million in gross proceeds in July 2024. Deloitte & Touche LLP audit fees were $878,391 for 2025 and $1,883,941 for 2024.
Cellectar Biosciences reported a narrower net loss for the year ended December 31, 2025 while advancing its radiotherapeutic pipeline. Net loss was $21,791,037 compared with $44,581,446 in 2024, as total operating expenses declined to $22,979,844 from $51,777,698.
Cash and cash equivalents were $13,196,033 at December 31, 2025, down from $23,288,607 a year earlier. Common shares outstanding rose to 4,240,129 from 1,535,996, and total stockholders’ equity decreased to $8,537,164 from $14,294,681. The company plans to submit a Conditional Marketing Authorization application for iopofosine I 131 to the European Medicines Agency in Q3 2026 for potential 2027 EU commercialization in Waldenström Macroglobulinemia, and is running a Phase 1b dose‑finding study of CLR 125 in triple negative breast cancer with early data expected by mid‑2026.
Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing cancer drugs based on its phospholipid ether drug conjugate (PDC) platform, which is designed to deliver radioactive and other payloads directly into tumor cells while sparing healthy tissue.
The lead radioconjugate, iopofosine I 131, showed strong results in Waldenstrom macroglobulinemia, with a 58.2% major response rate and 83.6% overall response rate in a pivotal CLOVER-WaM study of heavily pretreated patients, and has Breakthrough Therapy, Fast Track, Orphan Drug, PRIME and Rare Pediatric Disease designations across multiple indications. The FDA has outlined a path that could support accelerated and full approval, contingent on a Phase 3 confirmatory trial. Additional radioconjugate programs CLR 121125 and CLR 121225 are advancing toward or into early clinical studies in solid tumors such as triple-negative breast and pancreatic cancer.
Cellectar Biosciences, Inc. received an updated ownership report from Bleichroeder-related entities on a Schedule 13G/A. Bleichroeder LP, Bleichroeder Holdings LLC and Andrew Gundlach report beneficial ownership of 200,000 common shares, representing 4.61% of the company’s common stock.
The filing notes that Bleichroeder LP, a registered investment adviser, is deemed the beneficial owner because it manages these holdings for various clients. Those clients have the right to receive dividends and sale proceeds. The securities are stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of Cellectar Biosciences.